Patients with urologic cancer should be offered psycho-oncologic support to manage effects of emotional stressors.
Using mathematical analysis, researchers identified factors to help determine if containment or the elimination of an infection or tumor, is most effective.
Patients who were surveyed reported that the benefits of treatment with BV outweighed its risks.
Müllerian inhibiting substance (MIS) may be employed to protect ovaries from the effects of chemotherapy, according to research done with mice.
Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.
Cancer survivors who reported chronic neuropathic pain 5 years after diagnosis were approximately 50% less likely to retain their jobs than those without chronic neuropathic pain.
In vitro gametogenesis (IVG) offers hope for patients and survivors coping with disease-related and treatment-induced infertility, as well as providing a potentially unlimited supply of embryonic stem cells. However, legal and ethical issues need to be addressed before its widespread clinical use.
Using data from previous analyses and several state medical cannabis programs, investigators assessed how social attitudes, health issues, and state laws affect the use of cannabis among persons older than 50 years.
Oral cannabinoids can ease chronic pain and chemotherapy-related nausea, but researchers cite risks, as well.
A cursory look at hypnosis and where it may be used to offer an alternative and side-effect-free management of several aspects of care that can be beneficial to patients with cancer.
A cohort of participants in the MAP.3 trial completed the MENQOL questionnaire, and the findings shed light on the influence of changes in menopause-specific quality of life on aromatase inhibitor adherence in women at high risk for breast cancer.
Because treatment with pertuzumab could include adverse events similar to those observed with EGFR antagonists, such as diarrhea, researchers evaluated participants from 3 trials to determine the incidence and severity of diarrhea observed with pertuzumab.
In this study, researchers sought to identify physical, neurocognitive, and serologic markers that may correlate with self-reported fatigue before and after (neo)adjuvant chemotherapy for patients with early-stage breast cancer.
Many patients can still experience UA-RINV despite prophylactic therapy; therefore, researchers explored the effectiveness and safety of dual prophylactic therapy with an NK1 receptor antagonist and a 5-HT3 receptor antagonist.
An evaluation of the association of tissue factor, clinical risk factors, and other biomarkers measured at the time of initial VTE with recurrent VTE helps determine their predictive value for patients at high risk.
A comparison of administering the influenza vaccine concurrently with chemotherapy with that of administration within the cytopenic period during 3-week chemotherapy cycles determined which schedule was the optimal timing for vaccination administration in this group.
Researchers sought to evaluate the incidence of cancer-related cognitive impairment in patients with breast cancer in a large prospective, longitudinal, nationwide study. These findings address limitations in previous research.
A new system appears efficacious in preventing chemotherapy-related alopecia in women with breast cancer, according to a study presented at SABCS 2016.
Women who experienced menopause-related side effects were significantly less likely to adhere to their assigned tamoxifen therapy.
Investigators report on the efficacy of a structured prophylactic regimen of loperamide for 2 cycles to reduce incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer, at SABCS 2016.
In a poster presentation at SABCS 2016, researchers reported on the efficacy and safety of netupitant/palonosetron (NEPA) for the prevention of CINV in patients receiving highly or moderately emetogenic chemotherapy.
Researchers found that temporary pretreatment with LDA may protect normal breast tissue during chemotherapy for breast cancer in patients undergoing breast-conserving therapy, according to a study presented at SABCS 2016.
Perindopril, Bisoprolol Not Effective for Preventing Trastuzumab-mediated Left Ventricular RemodelingDecember 01, 2016
Perindopril, an angiotensin-converting enzyme (ACE) inhibitor, and the beta blocker bisoprolol protected against trastuzumab-related declines.
In patients with tumor lysis syndrome, rasburicase was significantly more effective in treating hyperuricemia and was associated with significantly shorter ICU stay.
Inducing vasoconstriction in the scalp of patients with breast cancer undergoing chemotherapy effectively reduces the amount of drug that reaches the hair follicles and hair-cell metabolism, minimizing one of the most dreaded side effects of treatment.
Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.
Loss of bone density related to chemotherapy and adjuvant therapy for breast cancer can lead to debilitating hip and vertebral fractures. This discussion discusses the impact of resistance training for these patients.
Large cohort study assesses the frequency of, and factors associated with, ototoxicity in childhood cancer survivors who received platinum agents without cranial irradiation.
The feasibility of an estradiol-releasing vaginal ring vs intravaginal testosterone cream for women with HR-positive stage I to III breast cancer using aromatase inhibitors who reported vaginal dryness, decreased libido, or dyspareunia is evaluated in a phase 2 study.
The Multinational Association of Supportive Care in Cancer (MASCC) and the European Society for Medical Oncology (ESMO) have updated their recommendations for the prevention of nausea and vomiting following multiple-day chemotherapy.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
- Pediatric Hepatocellular Carcinoma: Challenges and Solutions
- Earlier and Later Adult BMI Associated With Multiple Myeloma Risk
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|